April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.
Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.
The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
September 21st 2022An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.
Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.
Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.
Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
September 14th 2022Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.
Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
September 14th 2022Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.
Addition of Elotuzumab to KRd Yields Promising Responses in Newly Diagnosed Multiple Myeloma
August 1st 2022Results from a phase 2 study indicated that adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone with a minimal residual disease–adapted design boosted responses for those with newly diagnosed multiple myeloma.